149 related articles for article (PubMed ID: 9160265)
61. Characterization of focal liver lesions: use of mangafodipir trisodium (MnDPDP)-enhanced MR images.
Karabacakoğlu A; Adigüzel Y; Karaköse S; Kayaçetin E; Haykir R
Turk J Gastroenterol; 2006 Sep; 17(3):164-71. PubMed ID: 16941248
[TBL] [Abstract][Full Text] [Related]
62. Safety and efficacy of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials (safety).
Federle MP; Chezmar JL; Rubin DL; Weinreb JC; Freeny PC; Semelka RC; Brown JJ; Borello JA; Lee JK; Mattrey R; Dachman AH; Saini S; Harmon B; Fenstermacher M; Pelsang RE; Harms SE; Mitchell DG; Halford HH; Anderson MW; Johnson CD; Francis IR; Bova JG; Kenney PJ; Klippenstein DL; Foster GS; Turner DA
J Magn Reson Imaging; 2000 Jul; 12(1):186-97. PubMed ID: 10931579
[TBL] [Abstract][Full Text] [Related]
63. Diagnostic accuracy of portal-phase CT and MRI with mangafodipir trisodium in detecting liver metastases from colorectal carcinoma.
Regge D; Campanella D; Anselmetti GC; Cirillo S; Gallo TM; Muratore A; Capussotti L; Galatola G; Floriani I; Aglietta M
Clin Radiol; 2006 Apr; 61(4):338-47. PubMed ID: 16546464
[TBL] [Abstract][Full Text] [Related]
64. Defining intrahepatic biliary anatomy in living liver transplant donor candidates at mangafodipir trisodium-enhanced MR cholangiography versus conventional T2-weighted MR cholangiography.
Lee VS; Krinsky GA; Nazzaro CA; Chang JS; Babb JS; Lin JC; Morgan GR; Teperman LW
Radiology; 2004 Dec; 233(3):659-66. PubMed ID: 15516606
[TBL] [Abstract][Full Text] [Related]
65. MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers.
Wang C; Gordon PB; Hustvedt SO; Grant D; Sterud AT; Martinsen I; Ahlström H; Hemmingsson A
Acta Radiol; 1997 Jul; 38(4 Pt 2):665-76. PubMed ID: 9245962
[TBL] [Abstract][Full Text] [Related]
66. Mangafodipir trisodium-enhanced MRI of hepatocellular carcinoma: correlation with histological characteristics.
Kim JH; Kim MJ; Park YN; Lee JT; Kim BR; Chung JB; Choi JS; Kim KS; Kim KW
Clin Radiol; 2008 Nov; 63(11):1195-204. PubMed ID: 18929037
[TBL] [Abstract][Full Text] [Related]
67. MnDPDP-enhanced MR imaging of the liver. Correlation with surgical findings.
Kane PA; Ayton V; Walters HL; Benjamin I; Heaton ND; Williams R; Karani JB
Acta Radiol; 1997 Jul; 38(4 Pt 2):650-4. PubMed ID: 9245959
[TBL] [Abstract][Full Text] [Related]
68. Magnetic resonance imaging of acute myocardial ischemia using a manganese chelate, Mn-DPDP.
Pomeroy OH; Wendland M; Wagner S; Derugin N; Holt WW; Rocklage SM; Quay S; Higgins CB
Invest Radiol; 1989 Jul; 24(7):531-6. PubMed ID: 2502502
[TBL] [Abstract][Full Text] [Related]
69. Detection of hepatic metastasis: manganese- and ferucarbotran-enhanced MR imaging.
Choi JY; Kim MJ; Kim JH; Kim SH; Ko HK; Lim JS; Oh YT; Chung JJ; Yoo HS; Lee JT; Kim KW
Eur J Radiol; 2006 Oct; 60(1):84-90. PubMed ID: 16920315
[TBL] [Abstract][Full Text] [Related]
70. Manganese dipyridoxyl-diphosphate (MnDPDP) as a viability marker in patients with myocardial infarction.
Skjold A; Amundsen BH; Wiseth R; Støylen A; Haraldseth O; Larsson HB; Jynge P
J Magn Reson Imaging; 2007 Sep; 26(3):720-7. PubMed ID: 17729351
[TBL] [Abstract][Full Text] [Related]
71. Uptake of MnCl2 and mangafodipir trisodium in the myocardium: a magnetic resonance imaging study in pigs.
Eriksson R; Johansson L; Bjerner T; Briley Saebo K; Ahlström H
J Magn Reson Imaging; 2004 May; 19(5):564-9. PubMed ID: 15112305
[TBL] [Abstract][Full Text] [Related]
72. Hepatobiliary MR imaging: first human experience with MnDPDP.
Lim KO; Stark DD; Leese PT; Pfefferbaum A; Rocklage SM; Quay SC
Radiology; 1991 Jan; 178(1):79-82. PubMed ID: 1898539
[TBL] [Abstract][Full Text] [Related]
73. MR cholangiography with manganese dipyridoxyl diphosphate in the evaluation of biliary-enteric anastomoses: preliminary experience.
Hottat N; Winant C; Metens T; Bourgeois N; Devière J; Matos C
AJR Am J Roentgenol; 2005 May; 184(5):1556-62. PubMed ID: 15855115
[TBL] [Abstract][Full Text] [Related]
74. Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging.
Elizondo G; Fretz CJ; Stark DD; Rocklage SM; Quay SC; Worah D; Tsang YM; Chen MC; Ferrucci JT
Radiology; 1991 Jan; 178(1):73-8. PubMed ID: 1898538
[TBL] [Abstract][Full Text] [Related]
75. MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents.
Youk JH; Lee JM; Kim CS
AJR Am J Roentgenol; 2004 Oct; 183(4):1049-54. PubMed ID: 15385303
[TBL] [Abstract][Full Text] [Related]
76. Effects of Mn-DPDP and manganese chloride on hemodynamics and glucose tolerance in anesthetized rats.
Gao X; Sandberg M; Quach M; Bodin B; Johansson L; Jansson L
Acta Radiol; 2014 Apr; 55(3):328-34. PubMed ID: 23963152
[TBL] [Abstract][Full Text] [Related]
77. Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI.
Rockall AG; Planche K; Power N; Nowosinska E; Monson JP; Grossman AB; Reznek RH
Neuroendocrinology; 2009; 89(3):288-95. PubMed ID: 19023191
[TBL] [Abstract][Full Text] [Related]
78. Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate): clinical experience with a new contrast agent.
Rofsky NM; Weinreb JC
Magn Reson Q; 1992 Sep; 8(3):156-68. PubMed ID: 1390058
[TBL] [Abstract][Full Text] [Related]
79. A segmental hyperintensity area in the liver shown by delayed MR images with Mn-DPDP.
Suto Y; Weinreb JC; Rofski NM
J Comput Assist Tomogr; 1996; 20(4):647-9. PubMed ID: 8708073
[TBL] [Abstract][Full Text] [Related]
80. Fodipir and its dephosphorylated derivative dipyridoxyl ethyldiamine are involved in mangafodipir-mediated cytoprotection against 7β-hydroxycholesterol-induced cell death.
Laskar A; Andersson RG; Li W
Pharmacology; 2013; 92(3-4):182-6. PubMed ID: 24080534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
